Lapatinib interactions

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

In animal reproductive studies, administration of lapatinib to pregnant rats during the period of organogenesis and through lactation led to death of offspring within the first 4 days after birth at maternal exposures that were ≥ 3.3 times the human clinical exposure based on AUC following 1,250 mg dose of lapatinib plus capecitabine. (Lapatinib label, Warnings and precautions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

P-glycoprotein The concomitant use of colchicine capsules and inhibitors of P-glycoprotein (e.g. clarithromycin, ketoconazole, cyclosporine, etc.) should be avoided due to the potential for serious and life-threatening toxicity [see Warnings and Precautions (5.3) and Clinical Pharmacology (12) ] . (Colchicine label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid use of PRADAXA Capsules and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) [see Drug Interactions (7.1) and Use in Specific Populations (8.6) ] . (Dabigatran label, Warnings and precautions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (Pazopanib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

• Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (Rimegepant label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

• Avoid concomitant use with strong CYP3A4/P-gp inducers or strong CYP3A4/P-gp inhibitors that decrease or increase sirolimus concentrations ( 7.4 , 12.3 ). (Sirolimus label, Drug interactions)

Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (Sofosbuvir and velpatasvir label, Drug interactions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Effect of Other Drugs on TALZENNA Effect of P-gp Inhibitors Breast Cancer Avoid coadministration of TALZENNA with the following P-gp inhibitors: itraconazole, amiodarone, carvedilol, clarithromycin, itraconazole, and verapamil. (Talazoparib label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

Avoid strong CYP3A4 inducers. (Lapatinib label, Drug interactions)

Avoid concomitant use HYCAMTIN capsules with P-gp inhibitors or BCRP inhibitors. (Topotecan label, Drug interactions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (Lapatinib label, Warnings and precautions)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (Vincristine label, Drug interactions)

Avoid strong CYP3A4 inhibitors. (Lapatinib label, Drug interactions)

P-glycoprotein (P-gp) Inhibitors : Co-administration of P-gp inhibitors can increase afatinib exposure. (Afatinib label, Drug interactions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (Lapatinib label, Drug interactions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

P-gp Inhibitors Treatment of NVAF Based on clinical experience from the ENGAGE AF-TIMI 48 study, dose reduction in patients concomitantly receiving P-gp inhibitors resulted in edoxaban blood levels that were lower than in patients who were given the full dose. (Edoxaban label, Drug interactions)

…(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (Eltrombopag label, Drug interactions)

Coadministration of DESCOVY with other drugs that inhibit P-gp and BCRP may increase the absorption and plasma concentration of TAF. (Emtricitabine and tenofovir label, Drug interactions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (Lapatinib label, Drug interactions)

Concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) via P-gp inhibition; however, concomitant P-gp inhibitor use had no attributable effect on safety or treatment outcome of fidaxomicin-treated adult patients in controlled clinical trials. (Fidaxomicin label, Drug interactions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (Lapatinib label, Drug interactions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

…Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] . (Lomitapide label, Drug interactions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

Midazolam : Following coadministration of TYKERB and midazolam (CYP3A4 substrate), 24-hour systemic exposure (AUC) of orally administered midazolam increased 45%, while 24-hour AUC of intravenously administered midazolam increased 22%. (Lapatinib label, Drug interactions)

P-Glycoprotein (P-gp) Inhibitors Clinical Impact: The concomitant use of P-gp inhibitors can increase the exposure to morphine by two-fold and can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. (Morphine label, Drug interactions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Naldemedine label, Drug interactions)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (Lapatinib label, Drug interactions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (Lapatinib label, Drug interactions)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (Lapatinib label, Drug interactions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

Paclitaxel : In cancer patients receiving TYKERB and paclitaxel (CYP2C8 and P-gp substrate), 24-hour systemic exposure (AUC) of paclitaxel was increased 23%. (Lapatinib label, Drug interactions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (Lapatinib label, Drug interactions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (Lapatinib label, Drug interactions)

• Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (Rifaximin label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

TYKERB may prolong the QT interval in some patients. (Lapatinib label, Warnings and precautions)

Lenacapavir (LEN), a component of BIXLENVO, is a moderate inhibitor of CYP3A and a P-gp inhibitor. (Bictegravir, emtricitabine, and tenofovir alafenamide label, Drug interactions)

Dapagliflozin or dapagliflozin 3-O-glucuronide did not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 active transporters. (Dapagliflozin label, Drug interactions)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (Eribulin label, Drug interactions)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (Lapatinib label, Drug interactions)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (Lapatinib label, Drug interactions)

Substrates and Inhibitors of P-glycoprotein It has been shown in vitro that mefloquine is a substrate and an inhibitor of P-glycoprotein. (Mefloquine label, Drug interactions)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (Lapatinib label, Drug interactions)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (Lapatinib label, Drug interactions)

Strong P-glycoprotein (P-gp) Inhibitors In vitro studies indicated that silodosin is a P‑gp substrate. (Silodosin label, Drug interactions)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (Lapatinib label, Drug interactions)

Mechanism and Clinical Effect(s) Vepdegestrant is a P-gp inhibitor. (Vepdegestrant label, Drug interactions)